MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Johnson and Johnson

Затворен

СекторЗдравеопазване

153.18 -7.5

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

153.17

Максимум

165.34

Ключови измерители

By Trading Economics

Приходи

3.4B

Продажби

20M

23B

P/E

Средно за сектора

28.153

73.239

EPS

2.04

Дивидентна доходност

3.03

Марж на печалбата

15.235

Служители

138,100

EBITDA

652M

5.9B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+0.92% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.03%

3.06%

Следващи печалби

15.04.2025 г.

Следваща дата на екс-дивидент

19.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

26B

394B

Предишно отваряне

160.68

Предишно затваряне

153.18

Настроения в новините

By Acuity

46%

54%

152 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Johnson and Johnson Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.03.2025 г., 15:16 ч. UTC

Значими двигатели на пазара

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10.03.2025 г., 13:59 ч. UTC

Значими двигатели на пазара

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

21.03.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21.03.2025 г., 13:35 ч. UTC

Печалби
Горещи акции

Stocks to Watch Friday: J&J, Nike, FedEx, Micron -- WSJ

14.03.2025 г., 09:30 ч. UTC

Топ новини

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

7.03.2025 г., 01:00 ч. UTC

Топ новини

Finance Executives Seek Stability Amid Erratic Tariff Shifts -- WSJ

18.02.2025 г., 22:22 ч. UTC

Топ новини

Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan -- Update

14.02.2025 г., 13:00 ч. UTC

Топ новини

J&J's High Hopes for Heart-Rhythm Device Grounded by Safety Concerns -- WSJ

24.01.2025 г., 07:00 ч. UTC

Топ новини

Disasters Spawn New Businesses. The California Wildfires Will Do the Same. -- Barrons.com

22.01.2025 г., 21:39 ч. UTC

Печалби

These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22.01.2025 г., 19:41 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22.01.2025 г., 17:38 ч. UTC

Пазарно говорене
Печалби

J&J's Forex Headwind in Outlook Surprised Investors -- Market Talk

22.01.2025 г., 16:48 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22.01.2025 г., 14:51 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Ford, and More -- Barrons.com

22.01.2025 г., 14:09 ч. UTC

Топ новини
Печалби

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22.01.2025 г., 13:04 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Travelers, and More -- Barrons.com

22.01.2025 г., 12:47 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Agilysys, and More -- Barrons.com

22.01.2025 г., 12:34 ч. UTC

Печалби

Johnson & Johnson Earnings Narrowly Top But Dow Giant's Sales Guidance Light -- IBD

22.01.2025 г., 12:15 ч. UTC

Пазарно говорене

J&J's 2025 Sales View Misses Wall Street Estimates -- Market Talk

22.01.2025 г., 11:57 ч. UTC

Пазарно говорене
Печалби

J&J 4Q Sales Rise on Demand for Cancer Drugs, Medical Devices -- Market Talk

22.01.2025 г., 11:30 ч. UTC

Печалби

J&J's Earnings Beat Estimates But Guidance Is Mixed -- MarketWatch

22.01.2025 г., 11:23 ч. UTC

Топ новини
Печалби

J&J Reports Strong Revenue and Profit But Faces Challenges in 2025 -- WSJ

22.01.2025 г., 11:22 ч. UTC

Топ новини
Печалби

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22.01.2025 г., 11:20 ч. UTC

Печалби

Johnson & Johnson: Innovative Medicine 4Q Results Driven by In-Market Portfolio and Continued Uptake From Recently Launched Products, With 10 Brands Growing Double Digits >JNJ

22.01.2025 г., 11:20 ч. UTC

Печалби

Johnson & Johnson 4Q Worldwide MedTech Sales $8.19B >JNJ

22.01.2025 г., 11:20 ч. UTC

Печалби

Johnson & Johnson 4Q U.S. Sales $13.20B >JNJ

22.01.2025 г., 11:20 ч. UTC

Печалби

Johnson & Johnson: MedTech Business, With Addition of Shockwave Medical, Delivered Operational Sales Growth of 7.6% in 4Q >JNJ

22.01.2025 г., 11:20 ч. UTC

Печалби

Johnson & Johnson Sees 2025 Operational Sales of $90.9B-$91.7B >JNJ

22.01.2025 г., 11:20 ч. UTC

Печалби

Johnson & Johnson Sees 2025 Adjusted Operational EPS $10.75-$10.95 >JNJ

22.01.2025 г., 11:20 ч. UTC

Печалби

Johnson & Johnson Sees 2025 Adjusted Operational Sales Growth of 2.0%-3.0% >JNJ

Сравнение с други в отрасъла

Ценова промяна

Johnson and Johnson Прогноза

Ценова цел

By TipRanks

0.92% нагоре

12-месечна прогноза

Среден 167.36 USD  0.92%

Висок 185 USD

Нисък 152 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Johnson and Johnson през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

13 ratings

5

Купи

8

Задържане

0

Продай

Техническа оценка

By Trading Central

162.84 / N/AПодкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

152 / 386 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.